leadf
logo-loader
viewSareum Holdings PLC
(
AIM:SARFRA:RYH
)

Sareum's Tim Mitchell looks ahead to critical Phase II data from flagship Chk1 inhibitor

Sareum Holdings Plc (LON:SAR) CEO Tim Mitchell updates Proactive London's Andrew Scott on the progress being made by Sierra Oncology – its partner which is taking SRA737 through the clinic.

Sierra is currently using SRA737 in two early-stage ovarian cancer studies: one as a monotherapy and another in combination with low-dose gemcitabine – one of the most commonly-prescribed chemotherapies.

Preliminary data from these trials are expected within the next few months.

Sareum's also been investing a lot of time in its TYK2/JAK1 programme.

It has recently selected two molecules – one targeting autoimmune diseases and the other targeting certain types of leukaemia, lymphoma and solid tumours – for preclinical development.

Quick facts: Sareum Holdings PLC

Follow
AIM:SAR

Price: 6.6 GBX

Market Cap: £222.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Hochschild Mining reveals 'profitable' PEA on its heavy rare earths project...

Hochschild Mining Head of Investor Relations Charles Gordon joined Proactive New York to discuss the Peru-based gold and silver miner's recent developments within its heavy rare earths project, recently renamed Aclara. Gordon says the group recently revealed a preliminary economic assessment...

2 days, 5 hours ago

2 min read